HC Wainwright reiterated their buy rating on shares of GH Research (NASDAQ:GHRS - Free Report) in a research note published on Friday morning,Benzinga reports. HC Wainwright currently has a $40.00 price objective on the stock.
Separately, Canaccord Genuity Group dropped their price objective on shares of GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, November 18th.
Read Our Latest Stock Report on GHRS
GH Research Stock Down 4.6 %
NASDAQ GHRS traded down $0.41 during trading hours on Friday, hitting $8.57. 212,325 shares of the company were exchanged, compared to its average volume of 150,280. The company has a 50 day moving average of $8.44 and a two-hundred day moving average of $9.20. The firm has a market cap of $445.88 million, a price-to-earnings ratio of -10.85 and a beta of 0.84. GH Research has a 52-week low of $5.50 and a 52-week high of $14.99.
Institutional Investors Weigh In On GH Research
An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. increased its position in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 1.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,686,689 shares of the company's stock after buying an additional 85,000 shares during the quarter. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. 56.90% of the stock is owned by hedge funds and other institutional investors.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Stories
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
